HOME >> BIOLOGY >> NEWS
FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable

table HIV, compared to 60 to 70 percent of 82 subjects who received MK-0518 without FUZEON. FUZEON usage was associated with dramatically increased response rates in the study by approximately 50 percent.

Compliment new treatment guidelines

These findings are consistent with the recently updated HIV treatment guidelines, which emphasise undetectability as the goal of therapy in treatment-experienced patients, as well as the need to initiate multiple active anti-HIV agents simultaneously in order to achieve this goal.3-5 Recent clinical trials have convinced the authors of the guidelines that undetectable viral load should be the goal for all treatment-experienced patients. These trials, including POWER and RESIST, confirm the efficacy of the new drugs darunavir and tipranavir and emphasise that FUZEON should be the cornerstone to achieve undetectable levels of virus for treatment-experienced patients.


'"/>

Contact: Alexander Watson
alexander.watson@ketchum.com
44-771-267-5990
Ketchum
5-Oct-2006


Page: 1 2

Related biology news :

1. Providence health system shows investigational osteoporosis therapy increases bone mineral density
2. Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. Cooperative science program yields results
5. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
6. Smelling for first time results from knowing abnormalities in congenital loss of smell
7. BDSI announces positive phase III clinical trial results
8. Scientists meet to review Envisat results after 5 years of operations
9. Environment and exercise may affect research results, UA study shows
10. Preliminary results of largest scan of autism DNA information
11. Human trial results show excellent safety data, from Geovaxs DNA/MVA AIDS vaccines

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... PHOENIX (PRWEB) , ... July 03, 2020 , ... ... is proud to earn outstanding recognition and multiple awards for not only the ... the ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built ...
(Date:7/1/2020)... ... 01, 2020 , ... Catalent, a global leader in clinical ... packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating ... the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... In an ... on innovations in accelerated Point of Care Testing solutions (POCT). Check local listings for ... are collected at medical offices and are shipped to labs throughout the country. Results ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico ... patient's condition, treatment may be offered IV, intrathecal or with a combination. , A ... and the incidence continues to increase as individuals live longer. There is no cure, ...
(Date:7/1/2020)... N.C. (PRWEB) , ... June 29, 2020 , ... ... reported year to date growth of 40% in 2020, despite many obstacles created ... technology, MedShift aims to increase revenue for its partnered medical practices and medical ...
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
Breaking Biology Technology:
Cached News: